9:56 AM
 | 
Jan 04, 2017
 |  BC Innovations  |  Emerging Company Profile

Orum’s forum

How Orum is delivering antibodies into cells

A major downside of therapeutic antibodies is that they can’t touch intracellular targets: the biologics are too large to diffuse across cell membranes on their own, and those entering cells via endocytosis degrade before reaching the cytosol. Orum Therapeutics Inc.’s cell-penetrating antibody platform helps the biologics escape intracellular degradation to inhibit KRAS and other cytosolic proteins that are hard to target with small molecules.

According to CEO Sung Joo Lee, the platform is designed to get antibodies into cells via endocytosis, but get them out of endosomes before they are flagged for lysosomal degradation. Lee is Orum’s founder, and until August was head of research, Asia Pacific R&D at Sanofi.

The key component of the platform, which was developed by co-founder Yong-Sung Kim and colleagues, is an engineered, light chain variable domain (VL) that replaces both VLs in a standard IgG antibody....

Read the full 704 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >